TNFRSF17 and plasma cell myeloma: The technical methodology is built on the established “no-cell-left-behind” approach of the high-definition single-cell assay (HDSCA) workflow—previously validated clinically for various pathologies, including breast cancer [14], myocardial infarction [15], melanoma [15], prostate cancer [16], bladder cancer [17], colorectal cancer [18], and multiple myeloma [19,20]—and has been optimized for the detection of BCMA expression for the characterization of MM precursor cells in PC neoplasia.